PubMed Health⌕ Search

Biomedical subjects

R Argüero-Sánchez

Publications and source records attributed to R Argüero-Sánchez.

9 recordsLinked to original sources

[Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].

OBJECTIVE: To evaluate the fibrinogen and lipids response to diet plus bezafibrate in insulin-resistant patients with arterial hypertension and mixed hyperlipidemia. METHODS: A randomized double blind parallel design was used during a 90 days treatment period. Fibrinogen, lipids, insulin and peptide C assays as well as a glucose tolerance test were done at the start and end of treatment. The 28 patients received a hypolipemic diet low in refined sugars with bezafibrate added (400 mg/day) in 15 and a placebo in 13. RESULTS: The groups were similar in age, blood pressure and BMI. At the end of treatment, fibrinogen, cholesterol, triglycerides and LDL-C were lower in both groups as compared to the initial values, but only in the bezafibrate group there were: a) significant decrease in triglycerides (64 mg/dL, p 0.01); and b) marginal changes in fibrinogen (decreased 35 mg/dL, p = 0.09), total cholesterol (decreased 26 mg/dL, p = 0.10) and glucose/insulin ratio (increased from 4.4 to 5.2, p = 0.09). Bezafibrate lowered slightly the insulin level but did not affect peptide C. A correlation of changes in fibrinogen levels and the 60 min insulin concentration in the glucose tolerance test was higher in the bezafibrate group (r = 0.61) than in the placebo group (r = 0.23). CONCLUSIONS: In insulin resistant patients with high cardiovascular risk, bezafibrate and a placebo added to a hypolipemic diet decreased plasma fibrinogen. Bezafibrate lowered significantly the levels of triglycerides in these patients.

Adult↗

[De novo neoplasms in transplant patients].

To identify the number of patients with de novo tumors in organ transplant recipients, we collected the information from eleven hospitals of the Instituto Mexicano del Seguro Social with organ transplant programs. During a period of 9 years, we found only five cases of neoplasia. The median age was 26 years. All tumor occurred in renal transplant recipients. All patients received cyclosporine, azathioprine and steroids. One breast tumor, one renal carcinoma, two Kaposi's sarcoma and one angioleiomyosarcoma were found. The frequency of tumors in these patients is lower than reported by other authors, probably due, in our series to the fact that the patients were younger and the existence of a recently created transplant program with a short period of follow-up.

Female↗

The intraaortic counterpulsation balloon in cardiac surgery. The importance of opportune indication.

The results with the use of this device in patients who develop Low Cardiac Output Syndrome after cardiac surgery with extracorporeal circulation are analyzed. Special emphasis is given to the development of the opportune indication of this procedure, on the basis of a comparison of the results of the first few years to the most recent ones. Finally, the advantages of the prophylactic use of the Intraaortic Balloon Pump are commented.

Adult↗

[Thrombosis of mechanical heart valve prosthesis. Predisposing factors and results of surgical treatment].

Heart valve thrombosis is a serious complication. From February, 1995 to January, 1996, 19 patients were studied to identify predisposing factors and results of surgical management. Mean age was 47.3 years. Thirteen patients (73.6%) had an irregular surveillance of anticoagulation therapy. Fifteen patients showed low anticoagulation effect during their evolution. Sixteen patients were in functional class III and 80% (15 patients) showed imaging of thrombus in the echocardiographic study. All patients presented thrombus on both sides of the prothesis. There were no deaths, and 15 patients returned to functional class I. It was concluded that the main predisposing factor in this series of patients was deficient anticoagulation therapy, and surgical results are comparable to those other authors.

Adult↗